DiscoverFDA Drug Safety PodcastsFDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

Update: 2022-02-09
Share

Description

Listen to an audio podcast of the February 3, 2022, FDA Drug Safety Communication, FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib). We are re-evaluating this risk against the benefits of Ukoniq for its approved uses.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

U.S. Food and Drug Administration, Center for Drug Evaluation and Research